Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.

Lhermusier T, Voisin S, Murat G, Mejean S, Garcia C, Bataille V, Lipinski MJ, Carrié D, Sié P.

Int J Cardiol. 2014 Jul 1;174(3):874-6. doi: 10.1016/j.ijcard.2014.04.208. Epub 2014 Apr 26. No abstract available.

PMID:
24820749
[PubMed - in process]
2.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
[PubMed - indexed for MEDLINE]
3.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

PMID:
22789884
[PubMed - indexed for MEDLINE]
Free Article
4.

A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.

Straub N, Beivers A, Lenk E, Aradi D, Sibbing D.

Thromb Haemost. 2014 Feb;111(2):290-9. doi: 10.1160/TH13-08-0679. Epub 2013 Oct 24.

PMID:
24154566
[PubMed - indexed for MEDLINE]
5.

Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.

Coleman CI, Limone BL.

Thromb Haemost. 2014 Jan;111(1):103-10. doi: 10.1160/TH13-07-0557. Epub 2013 Oct 17.

PMID:
24136466
[PubMed - indexed for MEDLINE]
6.

Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.

Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.

PMID:
24172891
[PubMed - indexed for MEDLINE]
7.

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D.

J Am Coll Cardiol. 2014 Apr 22;63(15):1500-9. doi: 10.1016/j.jacc.2013.11.032. Epub 2013 Dec 12.

PMID:
24333493
[PubMed - indexed for MEDLINE]
8.

Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.

Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF.

Platelets. 2014;25(6):416-22. doi: 10.3109/09537104.2013.836175. Epub 2013 Oct 10.

PMID:
24111601
[PubMed - in process]
9.

Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.

Abergel E, Nikolsky E.

Vasc Health Risk Manag. 2010 Oct 21;6:963-77. doi: 10.2147/VHRM.S13263. Review.

PMID:
21057581
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor.

Davis EM, Knezevich JT, Teply RM.

Clin Pharmacol. 2013 Apr 19;5:67-83. doi: 10.2147/CPAA.S41859. Print 2013.

PMID:
23650452
[PubMed]
Free PMC Article
11.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
[PubMed - indexed for MEDLINE]
12.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

PMID:
23428007
[PubMed - indexed for MEDLINE]
Free Article
13.

Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.

Nührenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ.

Platelets. 2013;24(7):549-53. doi: 10.3109/09537104.2012.736045. Epub 2012 Dec 5.

PMID:
23216528
[PubMed - indexed for MEDLINE]
14.

Contraindications/special warnings and precautions for use of contemporary oral antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Alexopoulos D, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Vavuranakis M, Davlouros P, Ntalas I, Angelidis C, Hahalis G, Triposkiadis F, Vardas P, Stefanadis C, Goudevenos JA; GRAPE Investigators.

Circ J. 2014;78(1):180-7. Epub 2013 Nov 2.

PMID:
24189502
[PubMed - indexed for MEDLINE]
Free Article
15.

Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.

Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D.

Cardiology. 2013;124(4):252-8. doi: 10.1159/000347122. Epub 2013 Apr 9.

PMID:
23594617
[PubMed - indexed for MEDLINE]
16.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
[PubMed - indexed for MEDLINE]
17.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

PMID:
24486281
[PubMed - indexed for MEDLINE]
18.

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA.

Ann Intern Med. 2014 Feb 18;160(4):221-32.

PMID:
24727840
[PubMed - indexed for MEDLINE]
19.

Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.

Lhermusier T, Lipinski MJ, Drenning D, Marso S, Chen F, Torguson R, Waksman R.

J Interv Cardiol. 2014 Aug;27(4):365-72. doi: 10.1111/joic.12139. Epub 2014 Jul 19.

PMID:
25041356
[PubMed - in process]
20.

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.

Chyrchel B, Totoń-Żurańska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kołton-Wróż M, Wołkow P, Surdacki A.

Platelets. 2014 Oct 28:1-5. [Epub ahead of print]

PMID:
25350775
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk